

Nežádoucí účinky, jak vyplývá ze studií, jsou obecně podhlášeny, i přestože jejich následky jsou velkým břemenem jak pro zdraví pacientů, tak pro celkovou ekonomii, ačkoliv by se jim mohlo v mnoha případech předejít.

Při srovnávání různých farmakovigilančních systémů v zahraničí a jejich novinek z posledních pár let se ukazují i jiné možnosti, kterými

by se dalo podpořit sbírání dat o nežádoucích účincích. V různých oblastech je důraz kladen na elektronizaci a automatizaci v medicíně, jinde spíše na úpravy legislativy a nařízení s ukládáním povinností hlášení a jejich kontrolou zpětnou vazbou.

Podpořeno z programu Cooperation Pharmacology and Toxicology.

LITERATURA

1. info@aion.cz AC. 378/2007 Sb. Zákon o léčivech. Zákony pro lidi. Accessed January 18, 2022. <https://www.zakonyprolidi.cz/cs/2007-378?text=farmakovigilance>
2. Informační zpravodaj Nežádoucí účinky léčiv 1/2014, Státní ústav pro kontrolu léčiv. Accessed January 18, 2022. <https://www.sukl.cz/sukl/informacni-zpravodaj-nezadouci-ucinky-leciv-1-2014>
3. SÚKL. Informační zpravodaj Nežádoucí účinky léčiv 1/2011. 01252011;(1);<https://www.sukl.cz/sukl/informacni-zpravodaj-nezadouci-ucinky-leciv-1-2011>.
4. SÚKL. Informační zpravodaj Nežádoucí účinky léčiv 1/2021. 2021;(1). <https://www.sukl.cz/sukl/informacni-zpravodaj-nezadouci-ucinky-leciv-1-2021>
5. SÚKL. Informační zpravodaj Nežádoucí účinky léčiv 1/2014. 02102014;(1). <https://www.sukl.cz/sukl/informacni-zpravodaj-nezadouci-ucinky-leciv-1-2014>
6. Zsifkovits J, Zuba M, Geißler W, et al. Costs of unsafe care and cost effectiveness of patient safety programmes. Published online 2016. https://ec.europa.eu/health/sites/default/files/systems_performance_assessment/docs/2016_costs_psp_en.pdf
7. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. *Br J Clin Pharmacol.* 2004;57(2):121-126. doi:10.1046/j.1365-2125.2003.01875.x
8. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. *Br J Clin Pharmacol.* 2007;63(2):136-147. doi:10.1111/j.1365-2125.2006.02698.x
9. Strengthening pharmacovigilance to reduce adverse effects of medicines. European Commission - European Commission. Published 2008. https://ec.europa.eu/commission/presscorner/detail/de/MEMO_08_782
10. Canada H. Mandatory reporting of serious adverse drug reactions and medical device incidents by hospitals - Guidance document. Published August 11, 2020. Accessed January 18, 2022. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting/mandatory-hospital-reporting/drugs-devices/guidance.html>
11. Canada H. Module 1: Overview of Vanessa's Law and mandatory hospital reporting requirements. Published February 12, 2020. Accessed January 18, 2022. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting/mandatory-hospital-reporting/education/module-1.html>
12. Canada H. Adverse reactions, medical device incidents and health product recalls in Canada: 2019 summary report. Published December 11, 2020. Accessed January 18, 2022. <https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/adverse-reactions-incidents-recalls-2019-summary.html>
13. Canada H. Health Product InfoWatch: September 2021. Published September 29, 2021. Accessed January 16, 2022. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/health-product-infowatch/september-2021.html>
14. Yamaguchi M, Inomata S, Harada S, et al. Establishment of the MID-NET® medical information database network as a reliable and valuable database for drug safety assessments in Japan. *Pharmacoepidemiol Drug Saf.* 2019;28(10):1395-1404. doi:10.1002/pds.4879
15. Pharmaceuticals and Medical Devices Agency. MID-NET (Medical Information Database NETwork). MHLW Pharmaceuticals and Medical Devices Safety Information (FY2021) | Pharmaceuticals and Medical Devices Agency. 2021;(382). <https://www.pmda.go.jp/files/000241088.pdf#page=4>
16. Hitchen L. Adverse drug reactions result in 250 000 UK admissions a year. *BMJ.* 2006;332(7550):1109.
17. The Yellow Card scheme: guidance for healthcare professionals, patients and the public. GOV.UK. Accessed March 9, 2022. <https://www.gov.uk/guidance/the-yellow-card-scheme-guidance-for-healthcare-professionals>
18. Yellow Card: please help to reverse the decline in reporting of suspected adverse drug reactions. GOV.UK. Accessed March 9, 2022. <https://www.gov.uk/drug-safety-update/yellow-card-please-help-to-reverse-the-decline-in-reporting-of-suspected-adverse-drug-reactions>
19. Zhao Y, Wang T, Li G, Sun S. Pharmacovigilance in China: development and challenges. *Int J Clin Pharm.* 2018;40(4):823-831. doi:10.1007/s11096-018-0693-x
20. Sorgato A. New Drug Administration Law – New Rules and Liabilities -China. International Comparative Legal Guides International Business Reports. Accessed March 11, 2022. <https://iclg.com/briefing/13934-new-drug-administration-law-new-rules-and-liabilities-china>
21. Annual Report for National Adverse Drug Reaction Monitoring (2019) Released. Accessed March 11, 2022. http://english.nmpa.gov.cn/2020-04/10/c_500154.htm